CZCathy S. Zhong

Cathy S. Zhong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cathy S. Zhong has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Annemarei Ranta

    Department of Medicine, University of Otago, Wellington, New Zealand

    1 shared publication
  • Bruce C. V. Campbell

    Department of Neurology, The Royal Melbourne Hospital, Parkville, Australia

    1 shared publication
  • Campbell Le Heron

    Department of Neurology, Christchurch Hospital, New Zealand (C.S.Z., J.B., D.W., C.L.H., D.M., R.D., J.R., J.N.F., T.Y.W.).

    1 shared publication
  • Daniel Salazar

    Department of Medicine, Greymouth Base Hospital, New Zealand (D.S., K.S.).

    1 shared publication
  • Deborah Mason

    Department of Neurology, Christchurch Hospital, New Zealand (C.S.Z., J.B., D.W., C.L.H., D.M., R.D., J.R., J.N.F., T.Y.W.).

    1 shared publication
  • Duncan Wilson

    Department of Neurology, Christchurch Hospital, New Zealand (C.S.Z., J.B., D.W., C.L.H., D.M., R.D., J.R., J.N.F., T.Y.W.).

    1 shared publication

Latest Publications

  • Quantitative muscle ultrasound in adult spinal muscular atrophy. A pilot study

    by Luciana Pelosi, Miriam Rodrigues, Cathy Zhong, Shilpan Patel, Richard Roxburgh

    Introduction/Aims: Muscle ultrasound has been investigated in children with spinal muscular atrophy (SMA) and proposed as a potential biomarker of disease severity. We studied the ultrasound properties in adults with SMA to see whether they also have potential as markers of disease severity in older patients.Methods: Thickness and quantitative echogenicity of muscle and subcutaneous tissue were compared between eight prospectively recruited adult patients with SMA and eight age, sex and body mass index‐matched controls. Measurements were made in the dominant deltoid, biceps, triceps, forearm extensors, first dorsal interosseous, quadriceps, tibialis anterior, and gastrocnemius muscles. The muscle‐to‐subcutaneous (M:S) thickness and echogenicity ratios were also calculated. A mean value across all muscles as well as the individual values for each muscle were then calculated for each parameter in each subject and compared between the two groups. Significance was set at 0.05 after Bonferroni correction.Results: In the SMA patients, mean muscle thickness was significantly smaller (1.3 vs. 1.9 cm), muscle echogenicity higher (106 vs. 67 on the grayscale level), and subcutaneous thickness larger (0.9 vs. 0.3 cm) than in controls; M:S echogenicity ratio was significantly increased and M:S thickness ratio reduced in the patients. The most abnormal scores were found in the nonambulatory patients and the least abnormal in the ambulatory patients.Discussion: Ultrasound can detect and quantify the severity of muscle atrophy and structure in adult SMA, suggesting a potential role as a marker of disease severity, which will require validation by larger studies.


  • Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke

    by Cathy S. Zhong, James Beharry, Daniel Salazar, Kelly Smith, Stephen Withington, Bruce C.V. Campbell, Duncan Wilson, Campbell Le Heron, Deborah Mason, Roderick Duncan, et al.

    Background and Purpose: In ischemic stroke, intravenous tenecteplase is noninferior to alteplase in selected patients and has some practical advantages. Several stroke centers in New Zealand changed to routine off-label intravenous tenecteplase due to improved early recanalization in large vessel occlusion, inconsistent access to thrombectomy within stroke networks, and for consistency in treatment protocols between patients with and without large vessel occlusion. We report the feasibility and safety outcomes in tenecteplase-treated patients. Methods: We performed a retrospective analysis of consecutive patients thrombolyzed with intravenous tenecteplase at 1 comprehensive and 2 regional stroke centers from July 14, 2018, to February 29, 2020. We report the baseline clinical characteristics, rates of symptomatic intracranial hemorrhage, and angioedema. These were then compared with patient outcomes with those treated with intravenous alteplase at 2 other comprehensive stroke centers. Multivariable mixed-effects logistic regression models were performed assessing the association of tenecteplase with symptomatic intracranial hemorrhage and independent outcome (modified Rankin Scale score, 0–2) at day 90. Results: There were 165 patients treated with tenecteplase and 254 with alteplase. Age (75 versus 74 years), sex (56% versus 60% male), National Institutes of Health Stroke Scale scores (8 versus 10), median door-to-needle times (47 versus 48 minutes), or onset-to-needle time (129 versus 130 minutes) were similar between the groups. Symptomatic intracranial hemorrhage occurred in 3 (1.8% [95% CI, 0.4–5.3]) tenecteplase patients compared with 7 (2.7% [95% CI, 1.1–5.7]) alteplase patients ( P =0.75). There were no differences between tenecteplase and alteplase in the rates of angioedema (4 [2.4%; 95% CI, 0.7–6.2] versus 1 [0.4%; 95% CI, 0.01–2.2], P =0.08) or 90-day functional independence (100 [61%] versus 140 [57%], P =0.47), respectively. In mixed-effects logistic regression models, there was no significant association between thrombolytic choice and symptomatic intracranial hemorrhage (odds ratio tenecteplase, 0.62 [95% CI, 0.14–2.80], P =0.53) or functional independence (odds ratio tenecteplase, 1.20 [95% CI, 0.74–1.95], P =0.46). Conclusions: Routine use of tenecteplase for stroke thrombolysis was feasible and had comparable safety profile and outcome to alteplase.